Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

References

• Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960; 142:1497
   Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330 - 40; http://dx.doi.org/10.1056/NEJM199904293401706; PMID: 10219069
   PubMed Web of Science ®Google Scholar
• Tauchi T, Okabe S, Miyazawa K, Ohyashiki K. The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. Int J Oncol 1998; 12:1269 - 76; PMID: 9592185
   PubMed Web of Science ®Google Scholar
• Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86:726 - 36; PMID: 7606002
   PubMed Web of Science ®Google Scholar
• Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 1997; 159:4720 - 8; PMID: 9366395
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038 - 42; http://dx.doi.org/10.1056/NEJM200104053441402; PMID: 11287973
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, et al, IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408 - 17; http://dx.doi.org/10.1056/NEJMoa062867; PMID: 17151364
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145:913 - 23; http://dx.doi.org/10.7326/0003-4819-145-12-200612190-00008; PMID: 17179059
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16:2190 - 6; http://dx.doi.org/10.1038/sj.leu.2402741; PMID: 12399961
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, et al, European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041 - 51; http://dx.doi.org/10.1200/JCO.2009.25.0779; PMID: 19884523
   PubMed Web of Science ®Google Scholar
• Garg RJ, Kantarjian H, O’Brien S, Quintás-Cardama A, Faderl S, Estrov Z, Cortes J. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009; 114:4361 - 8; http://dx.doi.org/10.1182/blood-2009-05-221531; PMID: 19729517
   PubMed Web of Science ®Google Scholar
• Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009; 84:287 - 93; http://dx.doi.org/10.1002/ajh.21380; PMID: 19306355
   PubMed Web of Science ®Google Scholar
• Vasudevan KM, Garraway LA. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 2010; 347:105 - 33; http://dx.doi.org/10.1007/82_2010_66; PMID: 20549472
   PubMed Web of Science ®Google Scholar
• Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 2007; 35:231 - 5; http://dx.doi.org/10.1042/BST0350231; PMID: 17371246
   PubMed Web of Science ®Google Scholar
• Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29:233 - 42; http://dx.doi.org/10.1016/j.tibs.2004.03.006; PMID: 15130559
   PubMed Web of Science ®Google Scholar
• LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11:32 - 50; http://dx.doi.org/10.1016/j.drup.2007.11.003; PMID: 18166498
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851 - 63; http://dx.doi.org/10.1158/1535-7163.MCT-08-0017; PMID: 18606717
   PubMed Web of Science ®Google Scholar
• Notta F, Mullighan CG, Wang JC, Poeppl A, Doulatov S, Phillips LA, Ma J, Minden MD, Downing JR, Dick JE. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469:362 - 7; http://dx.doi.org/10.1038/nature09733; PMID: 21248843
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013; 121:489 - 98; http://dx.doi.org/10.1182/blood-2012-05-431379; PMID: 23223358
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19:6680 - 6; http://dx.doi.org/10.1038/sj.onc.1204091; PMID: 11426655
   PubMed Web of Science ®Google Scholar
• Schnell CR, Stauffer F, Allegrini PR, O’Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68:6598 - 607; http://dx.doi.org/10.1158/0008-5472.CAN-08-1044; PMID: 18701483
   PubMed Web of Science ®Google Scholar
• Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68:8022 - 30; http://dx.doi.org/10.1158/0008-5472.CAN-08-1385; PMID: 18829560
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351 - 6; http://dx.doi.org/10.1038/nm.1890; PMID: 19029981
   PubMed Web of Science ®Google Scholar
• Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009; 8:2204 - 10; http://dx.doi.org/10.1158/1535-7163.MCT-09-0160; PMID: 19671762
   PubMed Web of Science ®Google Scholar
• Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69:3955 - 62; http://dx.doi.org/10.1158/0008-5472.CAN-08-4450; PMID: 19366795
   PubMed Web of Science ®Google Scholar
• McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009; 69:5835 - 42; http://dx.doi.org/10.1158/0008-5472.CAN-08-4285; PMID: 19584292
   PubMed Web of Science ®Google Scholar
• Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 2008; 22:1728 - 36; http://dx.doi.org/10.1038/leu.2008.158; PMID: 18548093
   PubMed Web of Science ®Google Scholar
• Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009; 106:19503 - 8; http://dx.doi.org/10.1073/pnas.0905056106; PMID: 19850869
   PubMed Web of Science ®Google Scholar
• Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002; 21:5868 - 76; http://dx.doi.org/10.1038/sj.onc.1205724; PMID: 12185586
   PubMed Web of Science ®Google Scholar
• Sillaber C, Mayerhofer M, Böhm A, Vales A, Gruze A, Aichberger KJ, Esterbauer H, Pfeilstöcker M, Sperr WR, Pickl WF, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008; 38:43 - 52; http://dx.doi.org/10.1111/j.1365-2362.2007.01892.x; PMID: 18173550
   PubMed Web of Science ®Google Scholar
• Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005; 106:3948 - 54; http://dx.doi.org/10.1182/blood-2005-06-2209; PMID: 16105974
   PubMed Web of Science ®Google Scholar
• Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007; 109:5011 - 5; http://dx.doi.org/10.1182/blood-2006-01-015347; PMID: 17303698
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, Broxmeyer HE, Ohyashiki JH, Ohyashiki K. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007; 16:503 - 14; http://dx.doi.org/10.1089/scd.2007.9994; PMID: 17610380
   PubMed Web of Science ®Google Scholar
• Okabe S, Tauchi T, Tanaka Y, Katagiri S, Ohyashiki K. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. Stem Cells Dev 2012; 21:2939 - 48; http://dx.doi.org/10.1089/scd.2012.0016; PMID: 22642671
   PubMed Web of Science ®Google Scholar